Plasminogen activator inhibitor-1 in the evolution of stroke [PDF]
Srpski Arhiv za Celokupno Lekarstvo, 2004 Fibrinolytic activity in the acute stroke was examined by monitoring the level of plasminogen activator inhibitor-1 (PAI-1), as one of the indicators of fibrinolytic activity.
Jovanović Zagorka B. +8 more
doaj +1 more source
Elevated PAI-1 is associated with poor clinical outcomes in pediatric patients with acute lung injury. [PDF]
, 2009 PurposeDeposition of fibrin in the alveolar space is a hallmark of acute lung injury (ALI). Plasminogen activator inhibitor-1 (PAI-1) is an antifibrinolytic agent that is activated during inflammation. Increased plasma and pulmonary edema fluid levels of
Brady, Sandra +4 more
core +2 more sources
Increased hazard of myocardial infarction with insulin‐provision therapy in actively smoking patients with diabetes mellitus and stable ischemic heart disease: The BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial [PDF]
, 2017 Background In the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial, randomization of diabetic patients with stable ischemic heart disease to insulin provision ( IP
Brown, David L +3 more
core +2 more sources
RUDN Journal of Medicine, 2022 In the modern paradigm of public health protection, much attention is paid to the health of women in peri- and postmenopause, and a personalized approach prevails.
Irina S. Zhuravleva +4 more
doaj +1 more source
Plasminogen influence on the PAI-1 release by human platelets [PDF]
The Ukrainian Biochemical JournalРАІ-1 (plasminogen activator inhibitor type 1), as a major physiological inhibitor of tissue plasminogen activator and urokinase, plays a key role in the regulation of fibrinolysis in vivo.
O. I. Yusova +3 more
doaj +1 more source
PAI‐1 and atherothrombosis [PDF]
Journal of Thrombosis and Haemostasis, 2005 Plasminogen activator inhibitor-1 (PAI-1) is the major physiologic inhibitor of tissue-type plasminogen activator in plasma, and is elevated in a variety of clinical situations that are associated with increased risk of ischemic cardiovascular events. Recent insights into the biology of PAI-1 suggest that it is more than just an innocent bystander in ...
openaire +2 more sources
4 open, 2019 The anti-hyperglycemic drug, Metformin, is effective in treating early stages of diabetes and has been associated with a 37% decrease in cancer incidence. While the precise mechanisms for the anti-cancer effects of Metformin remain to be elucidated, this
Brücher Björn L.D.M., Jamall Ijaz S.
doaj +1 more source
Effect of dsRNA on Mesangial Cell Synthesis of Plasminogen Activator Inhibitor Type 1 and Tissue Plasminogen Activator [PDF]
, 2009 Background/Aims: Viral infections are a major problem worldwide and many of them are complicated by virally induced glomerulonephritides. Progression of kidney disease to renal failure is mainly attributed to the development of renal fibrosis ...
Merkle, Monika +4 more
core +1 more source
Recombinant PAI-1 therapy restores myoendothelial junctions and erectile function in PAI-1-deficient mice [PDF]
Andrologia, 2014 Myoendothelial junctions are specialised projections of cell : cell contact through the internal elastic lamina between endothelial cells and vascular smooth muscle cells. These junctions allow for endothelial cells and vascular smooth muscle cells to make direct membrane apposition and are involved in cell : cell communication.
P K, Kavoussi +9 more
openaire +2 more sources
Evidence that heparin but not hirudin reduces PAI-1 expression in cultured human endothelial cells [PDF]
, 1999 Heparin and other antithrombotic drugs besides their anticoagulant action could have a profibrinolytic effect. We have analyzed the effect of unfractionated heparin (UFH) and hirudin on PAI-1 gene expression in human umbilical vein endothelial cells ...
Montes, R. (Ramón) +4 more
core +1 more source